| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1b data readout example | PLN-101095 (oral, small molecule, dual selective inhibitor of integrins αvβ8 and αvβ1) immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology | |
phase 1b data readout example | PLN-101095 (oral, small molecule, dual selective inhibitor of integrins αvβ8 and αvβ1) immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology | |
phase 1b data readout example | PLN-101095 (oral, small molecule, dual selective inhibitor of integrins αvβ8 and αvβ1) immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Pliant Therapeutics, Inc.$1.12
-0.01 (-0.88%)
D 34Pipeline Score Fair Value Biotech · Clinical
Market Cap
74.92 M
EPS
-1.84
P/E Ratio
-
Value Trade
1.86 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
13.58 M
Operating CF
-19.23 M
Total Assets
202.60 M
Total Liabilities
37.43 M
Equity
165.17 M
D/E Ratio
12,345
4.31 %
Week
-6.92 %
1 Month
-6.92 %
3 Month
-20.58 %
6 Month
-96.03 %
5 Year
-95.16 %
All Time
Cash Data
Cash Position
170.89 M
Monthly Burn
6.41 M
Runway
24.9 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
757.15 K
52 Week Range
1.09 - 1.95
% held by Insiders
7.43 %
% held by Institutions
75.55 %
Enterprise Value
-67.18 M
Total Shares
61.91 M
Short %
4.76 %
Float Shares
54.30 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pliant Therapeutics, Inc.
358Total events
1Upcoming
69Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 1
Event history 357
May 30, 2026
◆Poster PresentationPLN-101095Presentation
Cohort Expansion of a Phase I Study of PLN-101095 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors
ICI-refractory advanced or metastatic solid tumorssource ↗
May 19, 2026
◆Oral PresentationPresentation
Pliant Therapeutics to participate in RBC Capital Markets Global Healthcare Conference fireside chat
Apr 30, 2026
▲First Patient DosedPLN-101095Trial
First patient dosed in FORTIFY Phase 1b indication expansion trial of PLN-101095 in combination with pembrolizumab
ICI-refractory advanced or metastatic solid tumorssource ↗
Apr 18, 2026
▲Oral PresentationPLN-101095Presentation
Oral presentation of updated Phase 1 data at AACR 2026
ICI-refractory advanced or metastatic solid tumorssource ↗
Apr 18, 2026
▲Trial InitiationPLN-101095Trial
Phase 1b indication expansion trial initiated
NSCLC, tumors with high tumor mutational burden, clear cell renal cell carcinomasource ↗
Apr 18, 2026
◆Enrollment UpdatePLN-101095Trial
Phase 1b indication expansion trial enrolling
NSCLC, tumors with high TMB, clear cell renal cell carcinomasource ↗
Apr 17, 2026
◆Oral PresentationPLN-101095Presentation
Phase 1 data oral presentation at AACR Annual Meeting 2026
checkpoint inhibitor refractory solid tumorssource ↗
Apr 17, 2026
◆Poster PresentationPLN-101095Presentation
Phase 1 data poster presentation at AACR Annual Meeting 2026
checkpoint inhibitor refractory solid tumorssource ↗
Apr 2026
▲First Patient DosedPLN-101095Trial
First participant dosed in FORTIFY Phase 1b indication expansion trial
ICI-refractory advanced or metastatic solid tumorssource ↗
Apr 2026
▲Oral PresentationPLN-101095Presentation
Oral presentation at AACR 2026 of updated Phase 1 data showing deepening of confirmed responses
ICI-refractory advanced or metastatic solid tumorssource ↗
Q2 2026
◆Topline ReadoutbexotegrastClinical Data
BEACON-IPF Phase 2b topline data anticipated in mid-2026
idiopathic pulmonary fibrosissource ↗
Drug Pipeline Intelligence
D34
Pipeline Score $82M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.1x
rNPV / MCap Top 45%
Micro Cap (rank 502 of 911)
Percentile RankPliant Therapeutics, Inc. faces pipeline headwinds (34/100), with $327M risk-adjusted pipeline value, led by FP-R01-MG-F2 in Idiopathic Pulmonary Fibrosis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FP-R01-MG-F2 Small molecule | Idiopathic Pulmonary Fibrosis | Phase 1 | NCT03183570 | 25% | $180M | COMPLETED | 21 | - | - | Jan 25, 2025 | - | Feb 4, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PLN-101095 | checkpoint inhibitor-refractory solid tumors | Phase 1b | 2026-05-11 | one confirmed overall complete response; two confirmed overall partial responses; one unconfirmed partial response; large increases in plasma interferon gamma (IFN- ) after 14 days of monotherapy; all responders maintained more than a 2-fold increase in IFN- at Week 10 Read More | Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featur Read More | |
PLN-101095 | checkpoint inhibitor-refractory solid tumors | Phase 1b | 2026-05-11 | one confirmed overall complete response; two confirmed overall partial responses; one unconfirmed partial response; large increases in plasma interferon gamma (IFN- ) after 14 days of monotherapy; all responders maintained more than a 2-fold increase in IFN- at Week 10 Read More | Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featur Read More | |
PLN-101095 | checkpoint inhibitor-refractory solid tumors | Phase 1b | 2026-05-11 | one confirmed overall complete response; two confirmed overall partial responses; one unconfirmed partial response; large increases in plasma interferon gamma (IFN- ) after 14 days of monotherapy; all responders maintained more than a 2-fold increase in IFN- at Week 10 Read More | Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featur Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PLRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PLRXPliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Pliant Therapeutics announced a presentation at the 2026 ASCO Annual Meeting, highlighting their Phase 1b trial of PLN-101095. This trial focuses on patients with ICI-refractory solid tumors, specifically non-small cell lung cancer and clear cell renal cell carcinoma. The study evaluates the safety and efficacy of PLN-101095 in combination with pembrolizumab.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featur
Pliant Therapeutics provided a corporate update and reported positive first quarter 2026 financial results, including dosing the first participant in the FORTIFY Phase 1b trial of PLN-101095. The company also presented updated Phase 1 trial data at AACR 2026, indicating encouraging anti-tumor activity in checkpoint inhibitor-refractory patients. PLN-101095, a dual selective integrin inhibitor, is designed to enhance immune response in tumors. Despite a reduced net loss, Pliant faces risks related to trial enrollment and drug development timelines.
Read more →PLRXPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Pliant Therapeutics will participate in the 2026 RBC Capital Markets Global Healthcare Conference. CEO Bernard Coulie and CFO Keith Cummings will engage in a fireside chat on May 19, 2026. The event will be accessible via a live webcast, with a replay available for 30 days. Pliant focuses on integrin-based therapeutics, particularly PLN-101095 for treating advanced solid tumors.
Read more →PLRXPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics has initiated the FORTIFY Phase 1b trial by dosing its first patient with PLN-101095, an oral dual selective integrin inhibitor, in combination with pembrolizumab. This trial targets patients with ICI-refractory advanced or metastatic solid tumors, focusing on safety and preliminary anti-tumor activity. Enrollment is currently underway, with interim data expected in 2027.
Read more →PLRXPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics presented updated data from its Phase 1 trial of PLN-101095 at the AACR 2026 Annual Meeting. The trial showed promising results in ICI-refractory solid tumors, with confirmed responses and significant tumor reduction. The company has initiated a Phase 1b trial to further explore this combination therapy.
Read more →PLRXPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics has announced the upcoming presentation of data from its Phase 1 clinical trial of PLN-101095 at the AACR Annual Meeting in April 2026. The presentation will occur during the Clinical Trials Mini Symposium and will be delivered by Dr. Timothy A. Yap from the University of Texas, M.D. Anderson Cancer Center. PLN-101095 is a novel dual integrin inhibitor aimed at addressing checkpoint resistance in advanced solid tumors. This presentation marks a significant step for Pliant as they evaluate the drug's safety and potential efficacy.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095
Pliant Therapeutics reported a corporate update and financial results for Q4 2025, highlighting the promising Phase 1 data for PLN-101095, which demonstrated significant antitumor activity in patients with checkpoint inhibitor refractory tumors. The company is initiating a Phase 1b trial to expand PLN-101095's indications based on encouraging response data. Financially, Pliant reduced its net loss compared to the previous year and maintains a strong cash position to support future operations. The ongoing trial data will be presented at the AACR Annual Meeting in April 2026.
Read more →PLRXPliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
Pliant Therapeutics, a clinical-stage biotechnology company, will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Bernard Coulie and CFO Keith Cummings will host a fireside chat on February 25 at 2:40 p.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days.
Read more →PLRX▼ -14.9%on this news
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Pliant Therapeutics has reported promising interim data for its investigational drug PLN-101095, which is being evaluated in patients with immune checkpoint inhibitor-refractory advanced solid tumors. The drug demonstrated significant antitumor activity, with one complete response and three partial responses among the participants, and showed stable disease or tumor reduction in 60% of patients. The company plans to accelerate development with a Phase 1b trial set to begin in 2026. The positive results support the potential of PLN-101095 as a novel treatment for patients with challenging cancers.
Read more →PLRXPliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Pliant Therapeutics, a clinical-stage biotechnology company, will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Key executives, including the CEO and CFO, will host a fireside chat on December 4 at 12:30 p.m. ET. The event will be accessible via a live webcast, with a replay available for 90 days.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Pliant Therapeutics provided a corporate update and reported its third quarter 2025 financial results. The company is advancing its oncology program with data expected in the fourth quarter of 2025 and is completing close-out activities for the BEACON-IPF trial. Additionally, Pliant has received regulatory clearance for a Phase 1 study of PLN-101325, targeting muscular dystrophies.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Pliant Therapeutics provided a corporate update and reported its second quarter 2025 financial results. The company announced the discontinuation of the bexotegrast development for idiopathic pulmonary fibrosis, citing an unfavorable risk-benefit profile. While restructuring efforts have largely been completed to maintain cash runway, the company expects to share additional data from its Phase 1 trial of PLN-101095 for solid tumors by the end of the year. Overall, the financial results showed a decrease in net loss but highlighted ongoing challenges in their drug development pipeline.
Read more →PLRX▼ -7.2%on this news
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics has announced the discontinuation of bexotegrast development in idiopathic pulmonary fibrosis (IPF) following an unfavorable risk-benefit analysis from the BEACON-IPF trial. The decision was made after recommendations from the Data Safety Monitoring Board due to increased risks of adverse events. Despite this setback, Pliant continues to advance its oncology programs, including PLN-101095, which is currently in Phase 1 trials.
Read more →PLRXPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
Pliant Therapeutics showcased clinical and preclinical data at the ATS 2025 Conference. Key presentations highlighted the antifibrotic effects of bexotegrast on various fibroblast populations and identified biomarkers relevant to interstitial lung disease (ILD). The findings suggest potential advancements in treatment options and clinical strategies for ILD patients.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Activities supporting the close out of BEACON-IPF continue topline data expected in the second quarter of 2025 Recently annou
Pliant Therapeutics has provided a corporate update and reported its financial results for Q1 2025, highlighting ongoing activities related to the BEACON-IPF trial. The company anticipates topline data from this trial in the second quarter of 2025. In addition, initial results from its oncology program with PLN-101095 show partial tumor responses among patients. However, the company faces challenges including a rising net loss and a significant workforce reduction aimed at extending its financial runway for future clinical trials.
Read more →PLRXPliant Therapeutics Announces Strategic Realignment of Workforce and Operations
Pliant Therapeutics announced a strategic restructuring that will reduce its workforce by approximately 45% to implement cost-saving measures. This decision aims to extend the company's cash runway while awaiting topline data from the BEACON-IPF trial, expected in the second quarter of 2025. The restructuring process is anticipated to be completed by the end of Q2 2025.
Read more →PLRXPliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Pliant Therapeutics has announced its participation in the 2025 American Thoracic Society International Conference, where it will present three scientific posters. Notably, the company has secured a featured oral presentation slot for its research on the antifibrotic activity of bexotegrast. The conference will take place in San Francisco from May 16-21, 2025.
Read more →PLRX▲ +10.4%on this news
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Pliant Therapeutics announced interim Phase 1 data for PLN-101095, showing a 50% objective response rate in patients with ICI-refractory advanced solid tumors. The drug, combined with pembrolizumab, demonstrated antitumor activity with confirmed partial responses. The trial is ongoing, with the fourth cohort currently enrolling at a higher dose.
Read more →PLRXPliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
Pliant Therapeutics has adopted a limited duration stockholder rights agreement to safeguard stockholder interests amid recent stock accumulations. The agreement aims to prevent any entity from gaining control without compensating all stockholders appropriately. The rights will be issued as a dividend and become exercisable under specific conditions, expiring on March 11, 2026.
Read more →PLRX▼ -59.9%on this news
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation
Pliant Therapeutics has announced the discontinuation of its BEACON-IPF Phase 2b trial following recommendations from its data safety monitoring board and an outside expert panel, due to an imbalance in adverse events. Despite this setback, there were indications of efficacy on the forced vital capacity endpoint, prompting the company to analyze the trial's complete data for future development plans. Pliant also reported a net loss of $49.7 million for Q4 2024, attributed to increased research and development costs. Looking forward, Pliant has sufficient cash reserves to fund operations for at least the next year.
Read more →PLRX▼ -59.9%on this news
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics announced the discontinuation of its BEACON-IPF Phase 2b trial for bexotegrast in idiopathic pulmonary fibrosis, prompted by safety concerns raised by the Data Safety Monitoring Board. Despite this, the trial revealed early efficacy indicators regarding forced vital capacity. Pliant intends to fully analyze the collected data before determining the next steps for bexotegrast's development, which may involve further trials and exploring different patient populations. The company continues its focus on advancing other products within its pipeline.
Read more →PLRX▲ +21%on this news
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Pliant has initiated assembly of outside panel of world-renowned exp
Pliant Therapeutics has announced the initiation of an external panel of experts tasked with reviewing unblinded data from the BEACON-IPF Phase 2b trial for bexotegrast, following a recommendation from the Data Safety Monitoring Board (DSMB) to pause enrollment and dosing. The company aims to maintain the integrity of the trial while seeking clarity on the DSMB's decision. The expert panel, which includes specialists in pulmonary diseases and biostatistics, will contribute to an expanded DSMB aiming to achieve a consensus recommendation within two to four weeks. Bexotegrast is being developed for idiopathic pulmonary fibrosis and has received significant designations from regulatory bodies.
Read more →PLRXPliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm
Pliant Therapeutics, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, which may lead to a class action lawsuit. The firm's action follows an announcement from Pliant Therapeutics regarding the voluntary pause of enrollment in their BEACON-IPF Phase 2b trial for bexotegrast. The decision to halt the study was prompted by recommendations from an independent safety panel after a data review. Investors who suffered losses are encouraged to seek legal advice for potential recovery options.
Read more →PLRX▼ -34.8%on this news· ran to -77% by day 3shared move
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-I
Pliant Therapeutics has announced the voluntary pause of enrollment and dosing in its BEACON-IPF Phase 2b trial. This decision follows recommendations made by the trial's Data Safety Monitoring Board (DSMB) after a prespecified data review. Current patients will remain in the trial while the company monitors data and continues discussions with global regulatory authorities. The impact of the DSMB's recommendation on the trial and drug development process is currently being assessed.
Read more →PLRXPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics, Inc. announced the grant of stock options to new Chief Technical Officer, Delphine Imbert, as part of an inducement for her employment. A total of 275,000 stock options were granted at an exercise price of $11.07 per share, vesting over four years. This move aligns with the company's strategy to strengthen its leadership as it advances its lead product candidate, bexotegrast, which is under active development for idiopathic pulmonary fibrosis.
Read more →PLRXPliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
Pliant Therapeutics has appointed Dr. Delphine Imbert as Chief Technical Officer. Dr. Imbert brings 25 years of experience in strategic clinical to commercial-stage manufacturing and drug development. She will oversee chemistry, manufacturing, and control activities as Pliant prepares for commercial-stage readiness. Dr. Imbert's expertise is expected to be crucial as the company advances its lead product, bexotegrast, towards approval for treating idiopathic pulmonary fibrosis.
Read more →PLRXPliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Pliant Therapeutics, Inc. has announced that its CEO, Dr. Bernard Coulie, will present at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025. The company is recognized for its innovative approach to developing therapies for fibrotic diseases, with its lead product candidate, bexotegrast, currently in advanced clinical trials. Additionally, Pliant has received significant regulatory designations for its products, underscoring the potential impact of its therapies in the treatment of idiopathic pulmonary fibrosis and other conditions.
Read more →PLRXPliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics, a biopharmaceutical company focused on therapies for fibrotic diseases, announced its participation in several upcoming investor events in December 2024. Key figures from the company, including CEO Bernard Coulie and CFO Keith Cummings, will engage with investors at the Evercore, Citi, Piper Sandler, and Oppenheimer conferences. The company is also progressing with its lead candidate, bexotegrast, currently involved in clinical trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Read more →PLRXPliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting 2024
Pliant Therapeutics presented positive clinical data on its drug bexotegrast at The Liver Meeting 2024, suggesting significant improvements in markers and symptoms for patients with primary sclerosing cholangitis (PSC). The Phase 2 INTEGRIS-PSC trial results indicated that bexotegrast was well tolerated and demonstrated antifibrotic properties, as well as improvements in liver stiffness and biochemistry. Additionally, novel biomarkers for PSC were identified, potentially assisting in disease progression monitoring. Overall, the findings reinforce Pliant's position in developing therapies for fibrotic diseases.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026
Pliant Therapeutics has provided a corporate update along with its third-quarter financial results for 2024. The company highlighted that its BEACON-IPF Phase 2b trial is on track for full enrollment in the first quarter of 2025, with data expected in mid-2026. Despite reporting a net loss of $57.8 million, Pliant maintains a strong financial position with $406.0 million in cash. The company is making progress on several therapeutic candidates, with a focus on idiopathic pulmonary fibrosis and solid tumors.
Read more →PLRX▲ +5.4%on this newsshared move
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its forthcoming participation in the Stifel 2024 Healthcare Conference, scheduled for November 19, 2024. Company executives Keith Cummings and Greg Cosgrove will engage in a fireside chat, offering insights into Pliant's business and therapeutic developments. Stakeholders can access the event via a live webcast, which will be available for 30 days post-event. Pliant is noted for its advancements in treatments for fibrotic diseases, including its lead candidate bexotegrast.
Read more →PLRXPliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting 2024
Pliant Therapeutics is set to present results from the INTEGRIS-PSC Phase 2a trial of bexotegrast at The Liver Meeting 2024. This oral presentation will provide insights into the drug's efficacy in treating primary sclerosing cholangitis (PSC), a rare liver disease with no approved therapies. The trial's results suggest that bexotegrast improves markers and symptoms of cholestasis and stabilizes liver fibrosis. The presentation is scheduled for November 18, 2024, and reflects the ongoing commitment of Pliant Therapeutics to address significant medical needs in fibrotic diseases.
Read more →PLRX▼ -5.9%on this news
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Pliant Therapeutics has appointed Dr. Gary Palmer as Senior Vice President of Medical Affairs. Dr. Palmer, who has over 25 years of experience, will oversee the company's global medical affairs activities, including scientific communications and patient advocacy. His previous roles include leadership positions at Bristol Myers Squibb and Myovant Sciences, where he managed portfolios related to pulmonary fibrosis and other therapeutic areas. This appointment aligns with Pliant's goal to advance its lead candidate, bexotegrast, toward commercial stage.
Read more →PLRXPliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
Pliant Therapeutics presented promising data on bexotegrast at the 2024 European Respiratory Society International Congress. Results from a Phase 2 trial indicated that bexotegrast effectively reduced type 1 collagen deposition in patients with idiopathic pulmonary fibrosis after 12 weeks. Additional findings suggested notable improvements in lung function metrics, hinting at the drug's potential as a therapeutic option for patients with fibrotic diseases. Overall, the presentations showcased encouraging outcomes that support the ongoing development of bexotegrast in clinical settings.
Read more →PLRXPliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
Pliant Therapeutics, a late-stage biopharmaceutical company, announced that it will present four studies at the European Respiratory Society International Congress 2024 in Vienna, Austria, from September 7-11, 2024. Notable presentations include evaluations of the antifibrotic activity of bexotegrast, along with safety and tolerability measures in idiopathic pulmonary fibrosis. The presentations reflect Pliant's commitment to advancing treatment options for fibrotic diseases and showcase the potential impact of their lead product candidate.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced c
Pliant Therapeutics reported positive data from a 12-week Phase 2a PET imaging trial of bexotegrast, showing reduced lung collagen and improved FVC in IPF patients. Additionally, positive long-term outcomes from the INTEGRIS-PSC trial reinforce the drug’s favorable safety profile. The company anticipates completing enrollment in the BEACON-IPF Phase 2b trial by early 2025, expecting results in mid-2026. Pliant also announced its financial results for the second quarter of 2024, revealing rising expenses but maintaining significant cash reserves.
Read more →PLRXPliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Pliant Therapeutics, Inc. announced that its CFO Keith Cummings and CMO Éric Lefebvre will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. The event will take place at the Intercontinental Hotel in Boston, Massachusetts. Interested parties can access a live webcast through Pliant's Investor Relations website, with a replay available for 30 days post-event. Pliant continues to advance its lead product candidate, bexotegrast, which is being developed for fibrotic diseases and has garnered various regulatory designations.
Read more →PLRXPliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across
Pliant Therapeutics announced positive results from the INTEGRIS-PSC Phase 2a trial for bexotegrast, showing it was well tolerated at a 320 mg dosage over 40 weeks. The trial demonstrated significant improvement in liver stiffness and alkaline phosphatase levels compared to placebo, along with ongoing benefits in hepatocyte function and bile flow. Following discussions with the FDA, Pliant is optimistic about the development path for bexotegrast in treating primary sclerosing cholangitis and addressing this unmet medical need.
Read more →PLRXPliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
Pliant Therapeutics, Inc. has appointed Steve Krognes to its Board of Directors, bringing over 30 years of financial and corporate strategy experience. Krognes previously served as CFO of Denali Therapeutics and Genentech and is recognized for his contributions to financial growth in the biopharmaceutical sector. His appointment is viewed positively, reinforcing the company's strategic evolution in developing therapeutics for fibrotic diseases. Pliant is currently advancing its lead candidate, bexotegrast, through various clinical trials.
Read more →PLRXPliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Pliant Therapeutics presented promising data from its bexotegrast program at the 2024 EASL International Liver Congress. The presentation included positive findings from the Phase 2a INTEGRIS-PSC trial, indicating that bexotegrast was well tolerated and effective in reducing liver fibrosis markers compared to placebo. Future data from this trial will be shared in the coming weeks, reinforcing the company's commitment to advancing its therapies for fibrotic diseases.
Read more →PLRXPliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
Pliant Therapeutics, Inc. presented data on their drug bexotegrast at the ATS 2024 International Conference. The presentations included safety and tolerability data from various clinical trials and highlighted the drug's distinct pharmacodynamic profile in fibrotic lung cells. Notably, bexotegrast demonstrated antifibrotic effects and modulated biomarkers of interstitial lung disease in patients with idiopathic pulmonary fibrosis. The company is furthering its development in the ongoing BEACON-IPF trial.
Read more →PLRXPliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 12-week treatment with Bexotegrast 160 mg resulted in
Pliant Therapeutics announced encouraging topline results from a Phase 2a clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). During the 12-week trial, patients treated with a 160 mg daily dose of bexotegrast showed a notable reduction in total lung collagen levels as measured by PET imaging. Additionally, improvements in lung function (FVC) and cough severity were consistently observed in treated patients compared to those receiving placebo. Importantly, bexotegrast was well tolerated without serious side effects throughout the study.
Read more →PLRXPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
Pliant Therapeutics announced that it will have two poster presentations at the European Association for the Study of the Liver International Liver Congress™. The presentations include an updated safety and efficacy analysis of the Phase 2a trial for the integrin inhibitor bexotegrast in primary sclerosing cholangitis. The congress is scheduled to take place in Milan, Italy from June 5-8, 2024. These presentations showcase Pliant's commitment to advancing treatments for fibrotic diseases.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results BEACON-IPF pivotal, adaptive Phase 2b 3 trial design implementation significantly accelerates bexotegrast development in IPF
Pliant Therapeutics provided a corporate update alongside its first quarter 2024 financial results, marking significant progress in its clinical trials and financial health. The company has implemented an adaptive trial design for its pivotal BEACON-IPF Phase 2b 3 trial for bexotegrast, which is projected to accelerate its development timeline. Additionally, data from a recently completed Phase 2a PET imaging trial are anticipated shortly. Despite a net loss reported for the quarter, Pliant has secured a loan facility and received regulatory approval for its muscular dystrophy program, PLN-101325.
Read more →PLRXPliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its participation in the 2024 American Thoracic Society International Conference, where it will present four scientific posters on Bexotegrast and its effects on idiopathic pulmonary fibrosis. The presentations include a featured oral presentation highlighting the safety and tolerability of Bexotegrast as a dual-selective inhibitor. The conference is scheduled to take place in San Diego, California from May 17-22, 2024, offering a platform for the latest research in fibrotic disease treatments.
Read more →PLRXPliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis Acceptance by European Union and other global health authorities of the pivotal, adaptive Phase 2b
Pliant Therapeutics has announced an accelerated development plan for bexotegrast in treating idiopathic pulmonary fibrosis (IPF) following its acceptance by the European Union and other global health authorities for a pivotal Phase 2b/3 trial. This innovative adaptive trial design aims to shorten the timeline to obtain Phase 3 data, allowing for a seamless transition between trial phases. Additionally, an amendment to its financing agreement has expanded Pliant's cash runway through 2026, enabling the swift progression of its drug development initiatives.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment
Pliant Therapeutics has released its fourth quarter 2023 financial results, reporting positive interim data from the Phase 2a INTEGRIS-PSC trial for bexotegrast. The drug demonstrated safety and efficacy in reducing liver fibrosis in patients with primary sclerosing cholangitis. Additionally, enrollment is ongoing in the BEACON-IPF trial for idiopathic pulmonary fibrosis. Despite a net loss increase, the company maintains a strong cash position to support future developments.
Read more →PLRXPliant Therapeutics to Participate in Upcoming Investor Conferences
Pliant Therapeutics has announced its participation in two upcoming investor conferences in March 2024. The company's president and chief medical officer will engage in a fireside chat at the TD Cowen 44th Annual Health Care Conference in Boston, followed by another at the Leerink Partners Global Biopharma Conference in Miami. Interested parties can access live webcasts from the investor relations section of Pliant's website, which will also archive the replays for 30 days after the events.
Read more →PLRX▼ -9.2%on this newsshared move
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Bexotegr
Pliant Therapeutics reported positive interim data from the Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected liver fibrosis. The 320 mg dose demonstrated a favorable safety profile with no severe adverse events and showed significant reductions in liver fibrosis markers after 12 weeks of treatment. Additionally, improvements in liver function and bile flow were observed through MRI imaging. The company plans to discuss the findings with regulatory authorities for potential next steps in development.
Read more →PLRXPliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Pliant Therapeutics, Inc. has announced that its CEO, Dr. Bernard Coulie, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The event is scheduled to start at 7:30 a.m. Pacific Time and will take place at the Westin St. Francis Hotel in San Francisco. Interested stakeholders can access the live presentation via the company’s website, with a replay available for 30 days post-event.
Read more →PLRX▼ -5.5%on this news
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSM
Pliant Therapeutics reported positive interim safety and efficacy data from its Phase 2a INTEGRIS-PSC trial for bexotegrast in patients with primary sclerosing cholangitis. The Data Safety Monitoring Board has recommended continuing the trial without modifications. The company also strengthened its leadership team with new appointments and announced a net loss of $41.5 million for the third quarter of 2023, signaling increased operational costs. Despite this, Pliant holds $523.6 million in cash to support long-term operations.
Read more →PLRX▲ +5.2%on this news· ran to +15% by day 3
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
Pliant Therapeutics, Inc. has announced that it will have three presentations at the upcoming 38th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting, taking place from November 1 to 5, 2023, in San Diego, will feature research on investigational therapies addressing solid tumors. The posters will be available on the company's website, highlighting the latest advancements in the field of cancer treatment.
Read more →PLRXPliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting 2023
Pliant Therapeutics has revealed positive interim results from the Phase 2a INTEGRIS-PSC trial of bexotegrast for treating primary sclerosing cholangitis (PSC). The findings will be presented at The Liver Meeting 2023, underscoring the significance of research for a disease with no existing FDA-approved therapies. Bexotegrast is a selective integrin inhibitor currently also in development for idiopathic pulmonary fibrosis (IPF). Further investigation, including additional data from the ongoing trial, is anticipated in 2024.
Read more →PLRXPliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
Pliant Therapeutics has appointed S. Mishima Gerhart as Chief Regulatory Officer. Gerhart brings over 20 years of regulatory expertise and a strong background in biotechnology and pharmaceuticals. She will lead the company's regulatory and quality strategies as Pliant advances its portfolio aimed at fibrotic diseases. Pliant's growth is reflected in this strategic hire, particularly as they enter late-stage development.
Read more →PLRX▲ +14.3%on this news
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Bexotegras
Pliant Therapeutics announced significant results from its Phase 2a INTEGRIS-PSC clinical trial of bexotegrast, which targets primary sclerosing cholangitis and suspected liver fibrosis. The treatment was well tolerated, showing no serious adverse events and achieving its primary and secondary endpoints. Notably, bexotegrast significantly reduced markers of liver fibrosis and improved liver biochemistry relative to placebo, suggesting its effectiveness. The company is set to share further interim data in 2024.
Read more →PLRXPliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Pliant Therapeutics, Inc. will hold a conference call and webcast to discuss interim results from the INTEGRIS-PSC Phase 2a trial focused on patients with Primary Sclerosing Cholangitis. The call is scheduled for September 26, 2023, at 8:00 a.m. ET, featuring management and a principal investigator from the University of Toronto. Participants will be able to access the event via telephone or webcast, and a replay will be available on the company's website.
Read more →PLRXPliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
Pliant Therapeutics has announced the appointment of Minnie Kuo as the new Chief Development Officer. Kuo, who has over 20 years of experience in clinical development across various therapeutic areas, will manage the company's clinical and nonclinical development activities. Her expertise in global clinical trial strategy and experience in inflammation and oncology are seen as valuable assets for Pliant's late-stage clinical efforts. Kuo expresses enthusiasm for joining a team dedicated to developing treatments for fibrotic diseases.
Read more →PLRXPliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
Pliant Therapeutics announced significant presentations at the European Respiratory Society International Congress 2023, including the final results from the INTEGRIS-IPF Phase 2a trial of bexotegrast. The trial demonstrated good tolerability and a durable treatment effect on forced vital capacity in patients with idiopathic pulmonary fibrosis. Additionally, data revealed reductions in pro-fibrogenic gene expression among treated patients. Pliant aims to advance bexotegrast's development as a potential treatment for fibrotic diseases.
Read more →PLRXPliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
Pliant Therapeutics, Inc. has announced three upcoming presentations at the European Respiratory Society International Congress 2023 in Milan, Italy. These presentations will address pivotal research on their drug bexotegrast and its effects on fibrogenesis in lung diseases. The event is scheduled to take place from September 9 to September 13, 2023, with several key topics related to interstitial lung disease and potential biomarkers.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegras
Pliant Therapeutics has announced its second quarter 2023 financial results along with significant advancements in its clinical pipeline, including the initiation of the Phase 2b BEACON-IPF trial for bexotegrast. The company reported positive long-term data from its INTEGRIS-IPF Phase 2a trial, showing improvements in patients with idiopathic pulmonary fibrosis (IPF). Additionally, Pliant has begun recruiting for its Phase 1 trial of PLN-101095 targeting solid tumors. Despite these advancements, the company faces a substantial net loss and increased operating expenses.
Read more →PLRXPliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
Pliant Therapeutics announced the initiation of the BEACON-IPF Phase 2b clinical trial for its investigational drug bexotegrast, targeting patients with idiopathic pulmonary fibrosis (IPF). This trial follows encouraging results from previous studies indicating that bexotegrast was well tolerated and provided preliminary benefits. The BEACON-IPF study will enroll approximately 270 patients across various global sites, assessing the drug's impact on lung function and disease progression. With a significant need for new IPF therapies, this trial represents a crucial milestone for Pliant Therapeutics.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results Positive long-term data from INTEGRIS-IPF 320 mg dose group at 24-weeks demonstrated bexotegrast was well tolerated with dura
Pliant Therapeutics has reported positive long-term data from its INTEGRIS-IPF trial, indicating that bexotegrast is well tolerated with durable improvements in idiopathic pulmonary fibrosis. The company also highlighted its strong financial position, with $577 million in cash to support operations through 2026, and upcoming clinical milestones including the BEACON-IPF Phase 2b trial. However, the company reported an increase in net loss and rising operational expenses compared to the previous year.
Read more →PLRX▼ -21%on this news
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures Bexoteg
Pliant Therapeutics announced promising results from their Phase 2a INTEGRIS-IPF trial of bexotegrast for idiopathic pulmonary fibrosis (IPF). The 320 mg dose showed good tolerability with no serious adverse events and significant improvements in forced vital capacity (FVC) and cough severity among treated patients. The data supports the initiation of a Phase 2b trial, BEACON-IPF, expected to begin in mid-2023 as the company aims to address the high unmet need for effective IPF treatments.
Read more →PLRXPliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
Pliant Therapeutics, a clinical-stage biotechnology company, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. CEO Bernard Coulie and CMO Éric Lefebvre will be hosting a fireside chat on April 19, 2023. The presentation will be accessible via a live webcast, with a replay available for 30 days on the company's website. This event highlights Pliant's focus on developing therapeutics for fibrosis.
Read more →PLRXPliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
Pliant Therapeutics announced it will present three scientific posters at the 2023 American Thoracic Society International Conference focused on bexotegrast, a drug candidate targeting idiopathic pulmonary fibrosis (IPF). Two of the posters received recognition and were selected for featured oral presentations. Data presented highlight the drug's mechanism of action and indicate promising results from the Phase 2a trial, particularly regarding its safety and antifibrotic activity. The presentations are set for May 21-24, 2023, in Washington, DC.
Read more →PLRXPliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Pliant Therapeutics has commenced enrollment in a Phase 2a trial for bexotegrast, following a positive review from an independent Data Safety Monitoring Board regarding its safety. This trial will evaluate a higher dose of bexotegrast in patients with primary sclerosing cholangitis (PSC), a condition for which there are no approved therapies. Over 600 participants have received bexotegrast without reporting severe adverse events. Interim data from the trial is expected in the third quarter of 2023.
Read more →PLRX▼ -9%on this newsshared move
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results - Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statis
Pliant Therapeutics has provided a corporate update along with its financial results for Q4 2022, highlighting positive interim data from the Phase 2a INTEGRIS-IPF trial for bexotegrast. The trial indicated a favorable safety profile and significant efficacy in increasing forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). The company also completed a significant equity financing round, extending its cash runway into the second half of 2026. While there was a reported net loss for the quarter, the organization remains optimistic about upcoming clinical data releases and milestones in 2023.
Read more →PLRXPliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
Pliant Therapeutics has announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors. Both bring extensive industry experience, which the company believes will be critical as it advances its product candidates towards late-stage clinical development. The appointments reflect Pliant's strategy to enhance its commercial capabilities and are seen as a positive step in its goal to develop novel therapeutics for fibrosis. The company remains focused on executing its development strategy in the competitive biotech landscape.
Read more →PLRXPliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Pliant Therapeutics has received FDA clearance for its Investigational New Drug application for PLN-101095, a dual selective integrin inhibitor aimed at treating solid tumors resistant to immune checkpoint inhibitors. The Phase 1 study is expected to begin in the second quarter of 2023, evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary antitumor activity. This advancement is seen as a critical development in addressing the significant unmet medical needs of cancer patients with suboptimal responses to existing therapies.
Read more →PLRXPliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Pliant Therapeutics has completed an upsized public offering, successfully selling 9,583,334 shares of its common stock at $30.00 per share, resulting in gross proceeds of around $287.5 million. The offering included the full exercise of an option by underwriters to purchase additional shares. The proceeds will support the development of Pliant's ongoing and future preclinical and clinical programs, reflecting the company’s focus on addressing fibrosis through innovative therapies.
Read more →PLRX▲ +5.2%on this newsshared move
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Pliant Therapeutics has appointed Lily Cheung as the new Chief Human Resources Officer. Cheung brings a wealth of experience with over 25 years in Human Resources across the biopharmaceutical and technology sectors, including leadership roles at Synthekine and Rigel Pharmaceuticals. The company emphasizes the importance of people and culture for its success and looks forward to Cheung's contributions in shaping its corporate environment.
Read more →PLRX▲ +5.2%on this newsshared move
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
Pliant Therapeutics has announced the pricing of its public offering, issuing 8,333,334 shares at $30.00 each, aiming to raise around $250 million. The capital will support the development of its fibrosis treatments, including bexotegrast and PLN-101095. The offering is set to close around January 27, 2023, provided all customary conditions are met. Despite the positive outlook on funding, there are inherent risks tied to market conditions and potential delays in clinical trials.
Read more →PLRX▲ +34.5%on this news· ran to +61% by day 3shared move
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
Pliant Therapeutics, a clinical-stage biotechnology company, has announced a public offering of $175 million in common stock, with an option for underwriters to purchase an additional $26.25 million. The company plans to use the proceeds to support its ongoing and future clinical programs, including bexotegrast and PLN-101095, among other corporate purposes. While the involvement of established financial institutions adds credibility, the offering is subject to market conditions and may not be completed as planned.
Read more →PLRX▲ +34.5%on this news· ran to +61% by day 3shared move
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmona
Pliant Therapeutics announced positive interim data from its INTEGRIS-IPF Phase 2a trial for bexotegrast, showing that the 320 mg dosage was well tolerated and resulted in a statistically significant increase in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). No patients experienced a 10% or greater decline in FVCpp, indicating a potential benefit in slowing disease progression. The company plans to continue the trial and expects further data in the second quarter of 2023, with potential plans for a Phase 2b clinical trial later in the year.
Read more →PLRXDeveloping Novel Treatments for Fibrotic Diseases JANUARY 2023 2023 PLIANT THERAPEUTICS Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ( we, us, our, Pliant or the "Company"). The informatio
Pliant Therapeutics is advancing its drug candidates for fibrotic diseases, notably bexotegrast, which is currently in Phase 2a trials. The company highlights its robust financial position and the potential for high-impact therapies to address significant unmet medical needs. However, Pliant acknowledges the inherent risks and uncertainties associated with drug development, including the regulatory landscape and clinical trial outcomes. The announcement reflects a commitment to combating conditions like Idiopathic Pulmonary Fibrosis (IPF), which currently lacks effective therapies.
Read more →PLRXPliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, where CEO Bernard Coulie will deliver an update. The conference is scheduled from January 9-12, 2023, with Pliant's presentation set for January 10 at 7:30 a.m. PT. Interested parties can access the presentation through the company's Investor Relations page, enhancing transparency for stakeholders.
Read more →PLRXPliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily, dual-selective αvß6/αvß1 integrin inhibitor, has received Orphan Drug Designation from the
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results SOUTH SAN FRANCISCO, CA., November 8, 2022 - Pliant Therapeutics, Inc. (Nasdaq PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f
Read more →PLRXPliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.
Read more →PLRXPliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Kathari
Read more →PLRX▲ +5.3%on this news
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification Interim 12-week data expected in early 2023 SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq:
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results SOUTH SAN FRANCISCO, CA., August 8, 2022 - Pliant Therapeutics, Inc. (Nasdaq PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics fo
Read more →PLRXPliant Therapeutics to Participate in BTIG Biotechnology Conference
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.
Read more →PLRXPliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective αvß6 / αvß1 integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the
Read more →PLRX▼ -13.2%on this newsshared move
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underw
Read more →PLRX▲ +159%on this newsshared move
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis PLN-74809 demonstrated a dose-dependent treatment effe
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks PLN-74809 t
Read more →PLRXPliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the presentation of two scientif
Read more →PLRXPliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
- IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end 2022 SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325,
Read more →PLRXPliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
Integrin target selected for development under 2019 collaboration following successful validation by Pliant Pliant to receive $4 million milestone payment and reimbursement in support of initiation of research and development activities SOUTH SAN FRANCISCO, Calif., June 16, 202
Read more →PLRXPliant Therapeutics Announces Presentations at the International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present tw
Read more →PLRXPliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company presented five s
Read more →PLRX▼ -11%on this newsshared move
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results $100 million Oxford loan facility extends cash runway to mid-2024 FDA Fast Track designation granted to PLN-74809 in IPF INTE
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results $100 million Oxford loan facility extends cash runway to mid-2024 FDA Fast Track designation granted to PLN-74809 in IPF INTEGRIS-IPF Phase 2a data readout in mid-2022 EMA Orphan D
Read more →PLRXPliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
Up to $100 million of non-dilutive capital from Oxford Finance LLC Extends expected cash runway to mid-2024 SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and
Read more →PLRXPliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective αvß6/αvß1 integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the pot
Read more →PLRXPliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
Five posters include data across biomarker, target engagement, and mechanism studies supporting development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Pliant selected for featured presentation at the ATS 2022 Respiratory Innovation Summit SOUTH SAN
Read more →PLRXPliant Therapeutics to Participate in Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D
Read more →PLRX▼ -7%on this news
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results SOUTH SAN FRANCISCO, CA., February 28, 2022 - Pliant Therapeutics, Inc. (Nasdaq PLRX), a clinical stage biotechnology company focused on discovering and developing nove
Read more →PLRXPliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg Trial initiation follows the FDA authorization of evaluation of long-term dosing of PLN-74809 at doses
Read more →PLRX▲ +11.1%on this news
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
Enrollment complete in INTERGRIS-IPF Phase 2a clinical trial with top-line data expected mid-2022 FDA has authorized evaluation of long-term treatment with PLN-74809 at doses up to 320 mg in IPF Company will present updates at the 40th Annual J.P. Morgan Healthcare Conference
Read more →PLRX▼ -10.4%on this newsshared move
Developing Novel Treatments for Fibrotic Diseases Corporate Presentation JANUARY 2022 Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the "Company"). The infor
Developing Novel Treatments for Fibrotic Diseases Corporate Presentation JANUARY 2022 Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the "Company"). The information set forth herein does not purport to be complete or
Read more →PLRXPliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results SOUTH SAN FRANCISCO, CA - November 9, 2021 - Pliant Therapeutics, Inc. (Nasdaq PLRX) ("the Company"), a clinical stage biotechnology company focused on discovering and developing novel
Read more →PLRXPliant Therapeutics to Participate in Piper Sandler Lung Day
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.
Read more →PLRXPliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis - Single dose administration of PLN-74809 achieved v 6 target engagement up to
Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis - Single dose administration of PLN-74809 achieved v 6 target engagement up to 98% in the lungs of IPF patients - All doses achieved ta
Read more →PLRXPliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results - SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed in extended Phase 1a trial of PLN-74809 in healthy volunte
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results - SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed in extended Phase 1a trial of PLN-74809 in healthy volunteers with no safety concerns identified - PLN-74809 Phase
Read more →PLRXPliant Therapeutics to Participate in the BTIG Biotechnology Conference
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BT
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results - PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021 - PLN-74809 Phas
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results - PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021 - PLN-74809 Phase 2a 12-week trials in IPF and PSC Currently on Track to
Read more →PLRXPliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 20th A
Read more →PLRXPliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the successful completion of a
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results - PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021 - PLN-74809
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results - PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021 - PLN-74809 Phase 2a 12-week trials in IPF and PSC Gained Momentum in
Read more →PLRXPliant Therapeutics to Participate in Upcoming Virtual Investor Events
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that management will be particip
Read more →PLRXPliant Therapeutics Announces Appointment of David Pyott to Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Py
Read more →PLRXPliant Therapeutics Announces Appointment of Gregory P. Cosgrove, M.D., FCCP, as Vice President of Clinical Development, IPF
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gregory P. C
Read more →PLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results - Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing - Phase 2a PET imaging trial of PLN-74809 in IPF
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 SOUTH SAN FRANCISCO - November 10, 2020 - Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the
Read more →PLRXPliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results - Raised over $175 million in initial public offering and concurrent private placement to advance lead product candidate P
Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results -Raised over $175 million in initial public offering and concurrent private placement to advance lead product candidate PLN-74809 for the treatment of idiopathic pulmonary fibrosis
Read more →Competitive Position
How PLRX ranks across every disease it competes inCompetitive Position is a premium feature
See how PLRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial